



## **Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th**

October 30, 2023

BOSTON--(BUSINESS WIRE)--Oct. 30, 2023-- [Astria Therapeutics, Inc.](#) (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results.

### **Webcast Information:**

Interested parties may join the webcast via the Investors section of the Astria website, [www.astriatx.com](http://www.astriatx.com), or with the following link: <https://lifescievents.com/event/astria-2/>.

Please connect to the webcast several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be required. The webcast will be archived for 90 days.

### **About Astria Therapeutics:**

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, [www.astriatx.com](http://www.astriatx.com), or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231030913007/en/): <https://www.businesswire.com/news/home/20231030913007/en/>

### **Investor Relations and Media:**

Elizabeth Higgins  
[investors@astriatx.com](mailto:investors@astriatx.com)

Source: Astria Therapeutics, Inc.